INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
INO-3107 Awarded The Innovation Passport Designation Under U.K. Government's Innovative Licensing And Access Pathway Granted By The ILAP Steering Group To INO-3107 For The Treatment Of Patients With Recurrent Respiratory Papillomatosis
Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP)
該獎項認可INO-3107有望成爲英國治療複發性呼吸道乳頭狀瘤（RRP）患者的第一治療選擇。
PLYMOUTH MEETING, Pa., July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innovative medicine as part of the U.K.'s Innovative Licensing and Access Pathway (ILAP). The designation, called an Innovation Passport, was granted by the ILAP Steering Group to INO-3107 for the treatment of patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating, chronic rare disease of the respiratory tract caused by HPV-6 and/or HPV-11.
賓夕法尼亞州普利茅斯會議，2024年7月11日/美通社/-- 納斯達克（NASDAQ:INO）的生物技術公司INOVIO專注於開發和商業化DNA藥物，以幫助治療和預防人類乳頭瘤病毒相關疾病、癌症和傳染病，今天宣佈，其主導的DNA藥物候選者INO-3107已被英國創新許可和獲取途徑（ILAP）的創新醫藥指定爲創新藥物。這一稱號，稱爲創新護照，由ILAP指導小組授予INO-3107，用於治療由HPV-6和/或HPV-11引起的呼吸道複發性乳頭狀瘤（RRP）患者，這是一種慢性罕見的呼吸道疾病。